18F-FAZA PET/CT肿瘤乏氧显像预测食管腺癌移植瘤放疗反应
本研究在食管腺癌小鼠模型中,用18F-FAZA PET/CT显像肿瘤乏氧,并探讨乏氧修饰剂尼莫拉唑的放射增敏作用。结果显示,治疗前T/B≥3.59可预测较差的放疗反应(灵敏度92.3%,特异度71.4%),乏氧肿瘤对放疗反应更差(P=0.0025);尼莫拉唑体外可降低乏氧放射抵抗(P<0.01),但体内增敏作用存疑,需进一步研究。
要点
- 治疗前18F-FAZA PET/CT的T/B≥3.59可预测食管腺癌移植瘤较差的放疗反应。
- 乏氧肿瘤(T/B≥3.59)对放疗的反应显著差于非乏氧肿瘤(P=0.0025)。
- 尼莫拉唑体外显著降低乏氧放射抵抗(P<0.01),但体内增敏作用存疑。
核心结论
- 18F-FAZA PET/CT测得的肿瘤组织乏氧可预测食管腺癌移植瘤模型的放疗反应。
- 尼莫拉唑的放射增敏作用存疑,需进一步研究。
研究设计与样本
- 研究采用人食管腺癌细胞系OACM5 1.C SC1进行体外MTS增殖实验,并在裸鼠皮下移植瘤模型中进行体内实验。
- 体内治疗连续5天每日给药:对照组(600μl 0.9% NaCl腹腔注射,N=5,n=7)、放疗组(5 Gy/d,N=11,n=20)、联合组(尼莫拉唑200 mg/kg/d腹腔注射,放疗前30分钟给药,N=13,n=21)。
- 治疗前进行18F-FAZA PET/CT显像并计算肿瘤与本底比值(T/B),计算相对肿瘤生长并进行组织学检查(乏氧、增殖)。
主要发现
- 治疗前18F-FAZA PET/CT的T/B≥3.59预测较差的放疗反应,灵敏度92.3%,特异度71.4%。
- 乏氧肿瘤(T/B≥3.59)对放疗的反应显著差于非乏氧肿瘤(T/B<3.59)(P=0.0025)。
- 体外实验显示,尼莫拉唑预处理显著降低乏氧放射抵抗(P<0.01)。
- 体内实验中,尼莫拉唑增强放疗抑制乏氧肿瘤区域癌细胞增殖的效果(Ki67,P=0.064),但未影响宏观肿瘤生长。
关键数值与推荐
- 治疗前18F-FAZA PET/CT的T/B≥3.59作为预测较差放疗反应的阈值,灵敏度92.3%,特异度71.4%。
- 乏氧肿瘤定义为T/B≥3.59,非乏氧肿瘤定义为T/B<3.59。
临床怎么用
- 在食管腺癌移植瘤模型中,治疗前18F-FAZA PET/CT的T/B≥3.59可用于预测放疗反应较差,可能辅助筛选适合乏氧修饰策略的患者。
- 尼莫拉唑在体内未显著影响宏观肿瘤生长,其放射增敏作用需进一步研究,暂不支持临床常规使用。
局限性
- 研究为食管腺癌小鼠移植瘤模型,结论外推至临床需谨慎。
- 尼莫拉唑体内增敏作用存疑,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Esophageal cancer is an aggressive disease with poor survival rates. A more patient-tailored approach based on predictive biomarkers could improve outcome. We aimed to predict radiotherapy (RT) response by imaging tumor hypoxia with 18F-FAZA PET/CT in an esophageal adenocarcinoma (EAC) mouse model. Additionally, we investigated the radiosensitizing effect of the hypoxia modifier nimorazole in vitro and in vivo. METHODS: In vitro MTS cell proliferation assays (OACM5 1.C SC1, human EAC cell line) were performed under normoxic and hypoxic (< 1%) conditions: control (100 μL PBS), nimorazole, irradiation (5, 10 or 20 Gy) with or without nimorazole. In vivo, subcutaneous xenografts were induced in nude mice (OACM5 1.C SC1). Treatment was given daily for 5 consecutive days: (A) control (600 μl NaCl 0.9% intraperitoneally (IP)) (N = 5, n = 7), (B) RT (5 Gy/d) (N = 11, n = 20), (C) combination (nimorazole (200 mg/kg/d IP) 30 min before RT) (N = 13, n = 21). N = number of mice, n = number of tumors. 18F-FAZA PET/CT was performed before treatment and tumor to background (T/B) ratios were calculated. Relative tumor growth was calculated and tumor sections were examined histologically (hypoxia, proliferation). RESULTS: A T/B ≥ 3.59 on pre-treatment 18F-FAZA PET/CT was predictive for worse RT response (sensitivity 92.3%, specificity 71.4%). Radiation was less effective in hypoxic tumors (T/B ≥ 3.59) compared to normoxic tumors (T/B < 3.59) (P = 0.0025). In vitro, pre-treatment with nimorazole significantly decreased hypoxic radioresistance (P < 0.01) while in vivo, nimorazole enhanced the efficacy of RT to suppress cancer cell proliferation in hypoxic tumor areas (Ki67, P = 0.064), but did not affect macroscopic tumor growth. CONCLUSIONS: Tumor tissue hypoxia as measured with 18F-FAZA PET/CT is predictive for RT response in an EAC xenograft model. The radiosensitizing effect of nimorazole was questionable and requires further investigation.
引用
- Melsens E, De Vlieghere E, Descamps B, et al. Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts. Radiat Oncol. 2018. PMID: 29514673. doi:10.1186/s13014-018-0984-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。